Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials is a research paper published in Cancers (2023). On theSindex it has a DataRank of 0. It has been cited 112 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH
Grant: R01 CA214916
National Institutes of Health
Grant: 7R01CA214916-04
Control of mutant p53 stability via the mevalonate pathway-DNAJA1 axis
FWCI
14.65
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals